Hepatologic Research
<
Inflammatory and Cardiovascular Disorders Programme
Group Leader
Montserrat García Retortillo
Since 2000, our research work has been dedicated to different clinical fields in Hepatology: the natural history of decompensated cirrhosis, ascites, renal insufficiency and infections; the virologic response to different therapeutic regimens against hepatitis C; adherence to hepatitis C treatment and the study, prevention and treatment of the psychiatric pathology associated with interferon and the progression of fibrosis in Hepatitis C, with or without HIV coinfection.
Recently, in the era of direct antiviral agents (DAA), we have focused on the treatment of hepatitis C in special populations with many barriers to HCV eradication, such as people with addictions and mental disorders.
We have also initiated different studies in hepatitis B (particularly regarding treatment adherence, predictors of treatment response and disease control and HBV reactivation), hepatocellular carcinoma (biomarkers, natural history, and impact of different aetiologies) and non-alcoholic steatohepatitis (NASH).
In 2019, our Group joined the LiverScreen Consortium, an international research group aimed to study the prevalence of liver fibrosis in high-risk groups within the general European population.
Research group
Members
José Antonio Carrión Rodríguez (Researcher)
Susana Coll Estrada (PhD Student)
Maria Teresa Broquetas González (PhD Student)
Núria Cañete Hidalgo (PhD Student)
Marc Puigvehí Badosa (PhD Student)
Rosa Fernández Rodríguez (Technician)
Ana Viu Soto (Technician)
Diego Lázaro Agudo (Research Assistant)
Main Publications
• Puigvehí M, de Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, de la Vega J, Calleja JL, Carrión JA. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV-genotype 1b with mild-moderate fibrosis: Results from a Real World Cohort. Liver Int 2019; 39(1): 90-97. IF 5.542. Q1.
Ongoing Research Projects
• Screening for liver fibrosis. A population-based study in European countries. The “LiverScreen” project
- Financing institution: Gilead Sciences (2018/8284/I) (2019); From January 2020: European Commission (European Union’s Horizon 2020 research and innovation programme) (847989)
- Period: from 2019 to 2024
- Principal investigator: García Retortillo, Montserrat
Participation in Research Networks
• The Liver Screen Consortium
- Financing Institution: Gilead Sciences
- Period: from 2019 to 2020
- Principal investigator: García Retortillo, Montserrat
Clinical Trials Signed in 2019
• Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
- Protocol: 2017-01
- Sponsor: Exact Sciences Corporation
- Budget: 6,071.62 €
- Principal investigator: Coll Estrada, Susana
• Cribaje de fibrosis hepática. Estudio poblacional en Europa. Proyecto “LiverScreen”
- Sponsor: Fundació Clínic per a la Recerca Biomèdica
- Principal investigator: García Retortillo, Montserrat
Outreach
Conferences, Seminars and Courses
• Montserrat Garcia Retortillo. Programa multidisciplinari per al tractament de l’hepatitis C en pacients amb addiccions: experiència de l’Hospital del Mar. L’hepatitis C a Barcelona. Objectiu: eliminació 2030. Agència de Salut Pública de Barcelona (ASPB), Barcelona, 15 October 2019.
Dissemination to Society and Initiatives of Citizen Participation
• MT Broquetas González. Malaltia hepàtica per greix, la nova epidèmia que afecta el fetge. Com detectar-la. Què s'ha de fer? Informació als pacients. I Congrés de Pacients Hepàtics. ASSCAT, AMTHC and Albi Espanya. Hotel d'Entitats Can Guardiola, Barcelona, 22 May 2019.
2019
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es